Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma ...Middle East

Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study evaluating the...

Read More Details
Finally We wish PressBee provided you with enough information of ( Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma )

Also on site :

• Kendall Jenner’s Venice Getaway Post Draws Sweet Message from Kris Jenner
• Democratic ‘Thinkers’ Already Plotting Project 2029
• 'Secret Lives of Mormon Wives' Stars Join 'Dancing with the Stars' Season 34